Publications by authors named "Robert G Deeter"

Claim this Profile
C
Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design.
Henry J Henk, Xiaoyan Li, Laura K Becker, Hairong Xu, Qi Gong, Robert G Deeter

J Comp Eff Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.
Derek Weycker, Oleg Sofrygin, Kim Seefeld, Robert G Deeter, Jason Legg

BMC Health Serv Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study.
M Blane Schilling, Connie Parks, Robert G Deeter

Exp Ther Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.
A Martin Lerner, Safedin H Beqaj, Robert G Deeter, James T Fitzgerald

In Vivo· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome.
A Martin Lerner, Howard J Dworkin, Tawfeeq Sayyed, Chung Ho Chang, James T Fitzgerald, Robert G Deeter

In Vivo· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome.
A Martin Lerner, Safedin H Beqaj, Robert G Deeter, James T Fitzgerald

In Vivo· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Michael W Simon, Douglas N Fish, Robert G Deeter

Drugs R D· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome.
A Martin Lerner, Safedin H Beqaj, Robert G Deeter, James T Fitzgerald

In Vivo· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.
A Martin Lerner, Safedin H Beqaj, Robert G Deeter, Howard J Dworkin, Marcos Zervos

Drugs Today (Barc)· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis